The Disinformation War: How to Spot Nicotine Myths on Both Sides

The nicotine information environment is polluted. On one side, the tobacco industry and its harm-reduction allies present reduced-risk products as essentially safe, downplaying addiction risks and the uncertainty around long-term health effects. On the other side, some tobacco control organizations present reduced-risk products as essentially dangerous, downplaying the evidence of reduced toxicant exposure and the potential for harm reduction. The truth—that non-combustible nicotine products are almost certainly far less harmful than cigarettes but not harmless, and that the net population effect depends on who uses them and how—is more nuanced than either side's messaging. Navigating this environment requires skills that public health has been slow to cultivate: the ability to evaluate competing claims critically, to recognize the kernels of truth in distorted narratives, and to hold uncertainty in mind without being paralyzed by it. Here's a field guide to the most common nicotine myths, and how to think about them.

Myth 1: 'Nicotine is as harmless as caffeine.' This claim, ubiquitous in vaping advocacy spaces, contains an important truth (the delivery system matters more than the molecule) wrapped in an oversimplification. Nicotine is more addictive than caffeine, has more significant cardiovascular effects, and has developmental impacts on fetal and adolescent brains that caffeine doesn't share. The appropriate comparison is not between nicotine and caffeine molecules but between the risk profiles of their respective delivery systems—and even then, the comparison is limited. How to evaluate: when you hear 'nicotine is like caffeine,' ask what specific comparison is being made and what evidence supports it. The claim is usually deployed to normalize nicotine use, not to inform risk assessment. It's not entirely false. It's just less true than its proponents suggest.

Myth 2: 'E-cigarettes are just as harmful as cigarettes.' This claim, sometimes implied by tobacco control messaging that emphasizes the harms of vaping without comparing them to smoking, is contradicted by the weight of toxicological evidence. E-cigarette aerosol contains far fewer toxicants at far lower concentrations than cigarette smoke, and the biomarkers of exposure in vapers are dramatically lower than in smokers. The claim is harmful because it discourages smokers from switching to a product that's almost certainly less dangerous. How to evaluate: when you hear 'vaping is harmful,' ask 'compared to what?' The absolute claim is true (vaping is not harmless). The relative claim—as harmful as smoking—is not supported by evidence. The most honest formulation is 'vaping is almost certainly far less harmful than smoking, but not risk-free, and the long-term effects are unknown.'

Myth 3: 'Flavors only serve to attract kids.' This claim, which underpins many flavor ban proposals, ignores the evidence that flavors are functionally important for adult smoking cessation—helping former smokers create a clean sensory break from tobacco and making the vaping experience satisfying enough to compete with cigarettes. It also ignores the adaptive behavior of consumers: when flavors are banned, some vapers return to smoking, and some switch to DIY mixing or illicit products. The claim is politically effective but empirically incomplete. How to evaluate: when you hear 'flavors are for kids,' ask whether the speaker acknowledges the adult cessation evidence and addresses the substitution effects of flavor bans. The claim is often deployed to simplify a complex policy trade-off into a moral binary.

Myth 4: 'Tobacco harm reduction is just an industry strategy to keep people addicted.' This claim, widespread in the tobacco control community, conflates the messenger with the message. The tobacco industry is indeed promoting harm reduction for commercial reasons—the same industry that spent decades denying the harms of smoking. But the evidence that non-combustible products are less harmful doesn't depend on the industry's motives. The industry didn't invent the toxicology; independent researchers confirmed it. Rejecting harm reduction because the industry supports it is an ad hominem argument—evaluating the claim based on who's making it rather than on its merits. How to evaluate: when you hear 'harm reduction is an industry strategy,' separate the evaluation of the products from the evaluation of the industry. The question 'are these products less harmful?' is independent of the question 'do we trust the companies selling them?' Conflating the two is rhetorically effective but analytically confused.

Myth 5: 'If we just educate people about the dangers of smoking, they'll quit.' This claim, implicit in the information-deficit model that has dominated tobacco control communication for decades, is contradicted by the persistence of smoking among populations that are fully aware of the risks—including physicians and nurses, who smoke at rates only slightly below the general population. Information is necessary but not sufficient for behavior change, especially when the behavior is driven by addiction. The myth persists because it's psychologically comforting (it implies that smokers who don't quit are ignorant or irrational) and politically convenient (it justifies communication-based interventions that are cheaper and less politically contentious than structural ones). How to evaluate: when you hear 'education is the answer,' ask what else is being proposed alongside education. The most effective tobacco control strategies combine education with structural interventions—taxation, regulation, and access to cessation support—that address the addiction itself, not just the information environment.

Myth 6: 'The science is settled.' This claim, made by both sides about different aspects of the nicotine debate, is almost always false. The science is settled on some questions (smoking causes cancer) and unsettled on others (the long-term health effects of vaping, the population-level impact of nicotine pouches, the net effect of flavor bans on smoking rates). Claiming that the science is settled on unsettled questions is a rhetorical strategy to foreclose debate, not an accurate characterization of the evidence. How to evaluate: when you hear 'the science is settled,' ask 'which science, on which question, with what degree of certainty?' The phrase is usually a signal that the speaker is advocating, not analyzing. The most honest answer to most nicotine policy questions is 'the evidence points in a direction, but there's genuine uncertainty, and reasonable people can disagree about the policy implications of that uncertainty.'

The most important skill for navigating the nicotine information environment is not knowledge of specific facts—though that helps—but a habit of asking the same critical questions of every claim, regardless of its source: What's being compared to what? What's the evidence? What's the uncertainty? Who benefits if I believe this? The nicotine debate is unusually polarized because the stakes are high, the evidence is complex, and the participants have strong institutional and financial interests. In such an environment, the most reliable guide is not any single source but the discipline of applying the same skepticism to every source—including the ones you're inclined to trust.